GlassScriptPhysician profile
Daisy Mabel Carlson
NPI 1487085726
$1,532.14
in general payments reported to CMS, 2019-2025
21 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $150 · 2023: $57.26 · 2024: $207 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.90 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $169.12 | 2025 | Gemtesa, Myfembree |
| Actelion Pharmaceuticals US, INC. | $137.13 | 2024 | Opsumit, Uptravi |
| Agile Therapeutics, INC. | $135.97 | 2021-2023 | Twirla |
| Eisai INC. | $123.13 | 2021 | |
| Exeltis, USA INC. | $120.93 | 2025 | Twirla, Slynd |
| Biogen, INC. | $118.60 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $114.39 | 2021 | |
| Amgen INC. | $107.74 | 2022 | |
| Mayne Pharma Commercial LLC | $80.28 | 2025 | |
| Sage Therapeutics, LLC | $72.39 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $66.95 | 2022-2025 | |
| Organon LLC | $65.23 | 2021-2023 | Nexplanon |
| Millicent US INC | $43.37 | 2024-2025 | Femlyv |
| Incyte Corporation | $35.66 | 2024-2025 | Jakafi |
| Pfizer INC. | $32.47 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.75 | 2024 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $20.32 | 2025 | Vpriv |
| Exact Sciences Corporation | $16.88 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $16.21 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $16.00 | 2025 | Qelbree |
| Vertex Pharmaceuticals Incorporated | $15.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.